Mounting evidence indicates that DUXAP10 is abnormally highly expressed in a variety of cancers, including HCC, lung cancer, glioma, RCC, PTC, PCa, CML, OC, GC, PC, BC, CRC, and ESCC. Here, DUXAP10 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.